aguillerm, Author at Enterosys

Enterosys welcomes its new CEO

a new CEO and a new vision

Enterosys participates in AFSSI Connexions in Lyon

The annual preclinical research meeting

Enterosys participates in the opening meeting of the LEARN project

LEARN project: Nutritional models of NASH, biomarkers and mechanisms

Enterosys CSO elected to the AFSSI Board of Directors.

Enterosys participates in strategic discussions on future challenges for preclinical CROs

Enterosys becomes a member of the Pharmabiotic Research Institute (PRI)

Our CRO is part of the biotech ecosystem developing microbiome-based medicinal products

Research

Categorie

Enterosys participates in Biofit 2022 in Strasbourg

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing...

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in a hybrid format. This hybrid event will be held both in-person and online. Enterosys will be present with a validated, complete and...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks Preterm infants are highly susceptible to oxidative stress due...

Targeting our second brain using prebiotics

The discovery of intestinal actors, such as enterosynes that are able to modulate the ENS-induced duodenal contraction, opens new research avenues. Among all the intestinal factors, gut microbes and their role that they play in controlling glycaemia remain a...

Glucose is an Enterosyne with deleterious impact of insulin sensitivity

Targeting the enteric nervous system that controls gut motility is now considered as an innovative therapeutic approach in T2D. Indeed, it may limit intestinal glucose absorption and restore the gut‐brain axis to improve insulin sensitivity So far, little is known...

aguillerm